Core Corporate Strategy and Evolution

Lingmed structured its operational roadmap into distinct chronological five-year phases: * The First Five Years (2013–2018): Concentrated on introducing renowned global pharmaceutical and life science intelligence databases into the Chinese domestic market, notably securing exclusive distribution and sales rights for platforms such as EvaluatePharma (UK) and Biotechgate (Switzerland). * The Second Five Years (2018–2023): Expanded operations into active cross-border partnering and deal-making services under the Linkedbio Partnering brand, successfully facilitating multiple international licensing and alliance agreements. * The Third Five Years (2023–Present): Focused on scaling its proprietary in-house Linkedbio Database targeting Asia-Pacific biomedical innovations, alongside advancing high-level cross-border communication and asset transactions.

Products Offered

Lingmed acts as a primary commercial agent and regional distributor for several top-tier global healthcare databases, analytical software tools, and proprietary datasets:

1. Biotechgate Database: Developed by Venture Valuation in Switzerland, this comprehensive global tool covers more than 50,000 pharmaceutical, biotechnology, and medtech companies, over 72,000 innovative pipeline products, thousands of active licensing opportunities, and detailed business development contact leads. Lingmed serves as its exclusive commercial partner for the Chinese market.
2. Linkedbio Database: An in-house developed intelligence platform built by Lingmed that specifically monitors and maps out emerging life science innovations across the Asia-Pacific region.
3. Third-Party Intelligence Partnerships: Lingmed has historically partnered with major data providers to distribute products like EvaluatePharma, Cortellis, Decision Resources, and Baidu-backed healthcare intelligence sources across targeted Asian and European jurisdictions.
4. Xplico Evaluator: An Excel-based financial add-on forecasting tool designed to assist small and medium-sized biotechnology and pharmaceutical enterprises with sales forecasting and clinical asset deal valuation.

Services Offered

Lingmed provides a diverse portfolio of professional advisory, technical execution, and commercialization services designed to streamline international market entry and asset optimization:

• Cross-Border Business Development (BD) and Licensing: Lingmed facilitates both License-In and License-Out arrangements, helping Western biotechnology firms find ideal Chinese commercial partners, investors, or regional licensees, and vice versa. This includes target profiling, partner shortlisting, roadshow coordination, virtual meeting facilitation, and deal structuring.
• Mergers & Acquisitions (M&A) and Fundraising Support: The company advises on complex financial transactions, capital raising initiatives, and strategic alliance management for emerging healthcare firms.
• Regulatory Affairs and Market Access: Assists international manufacturers with navigation of complex regulatory frameworks, technical transfers, and submission pathways toward China's National Medical Products Administration (NMPA) to secure rapid commercial approval.
• Clinical Trial Management: Supports clients in identifying appropriate clinical innovation opportunities and orchestrating clinical development strategies—including Multi-Regional Clinical Trials (MRCT), importation trials, and patient recruitment coordination—across the European Union and China.
• Market Research and Consulting: Delivers custom market analysis, competitor benchmarking, executive strategy workshops, hospital and Principal Investigator (PI) surveys, and specialized valuation training sessions.